💉FDA Approves Aletta, First Autonomous Blood-Draw Machine
Aletta is the first robot that can draw blood without a human
TL;DR
Aletta, the first autonomous blood-draw machine, has been FDA-approved for non-hospital use. It successfully drew blood on the first attempt in 94.5% of cases, reducing reliance on phlebotomists.
Aletta, the first autonomous blood-draw machine, has been approved by the FDA for use in non-hospital settings. This machine uses near-infrared light and ultrasound to identify veins, ensuring a high success rate of 94.5% in clinical trials. A single phlebotomist can oversee up to three Aletta machines, addressing the high turnover rate of phlebotomists. Aletta's technology is designed to work for all skin tones and includes multiple safety features to prevent complications.
Key Points
Aletta uses near-infrared light and ultrasound to identify veins, ensuring a 94.5% success rate in clinical trials.
A single phlebotomist can supervise up to three Aletta machines, addressing the 25% annual turnover rate of phlebotomists.
Aletta's technology works well for all skin tones, with unpublished data showing no effect of skin tone on performance.
A U.S.-based trial is planned for next year to assess sample quality and routine laboratory tests.
Aletta includes sensors that track arm movement and needle position, halting the process if something goes wrong.
Why It Matters
If you're a lab or clinic dealing with phlebotomist shortages, Aletta could be a game-changer. It successfully drew blood on the first attempt in 94.5% of cases, and a single phlebotomist can oversee up to three machines. This reduces reliance on phlebotomists, who have a median annual turnover rate of nearly 25%. Aletta's technology also works well for all skin tones, ensuring equitable care.
Frequently Asked Questions
Why does this matter?
If you're a lab or clinic dealing with phlebotomist shortages, Aletta could be a game-changer. It successfully drew blood on the first attempt in 94.5% of cases, and a single phlebotomist can oversee up to three machines. This reduces reliance on phlebotomists, who have a median annual turnover rate of nearly 25%. Aletta's technology also works well for all skin tones, ensuring equitable care.
What happened?
Aletta, the first autonomous blood-draw machine, has been FDA-approved for non-hospital use. It successfully drew blood on the first attempt in 94.5% of cases, reducing reliance on phlebotomists.
Comments
Be the first to comment
Enjoyed this article?
Get it daily. 7am. Free. Reads in 5 minutes.
Join 3,462 builders reading daily.